About
This medication combines Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, with Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor. Sitagliptin enhances the body's natural ability to lower blood glucose by increasing active incretin hormone levels, which stimulate insulin release and suppress glucagon secretion. Dapagliflozin works by blocking glucose reabsorption in the kidneys, leading to increased urinary glucose excretion. This combination provides a complementary mechanism of action to improve glycemic control in adults with type 2 diabetes mellitus. Additionally, dapagliflozin offers significant cardiovascular and renal benefits, including reducing the risk of heart failure hospitalization and slowing the progression of kidney disease, making this a comprehensive treatment option.
Uses
- Management of type 2 diabetes mellitus.
- Improvement of glycemic control in adults.
- Used as an adjunct to diet and exercise.
- When monotherapy with sitagliptin or dapagliflozin is inadequate.
Directions For Use
Take this medication orally once daily in the morning, with or without food, as directed by your healthcare provider.
Benefits
- Effective blood glucose lowering.
- Reduces HbA1c levels significantly.
- Low risk of hypoglycemia when used alone.
- Potential for modest weight loss.
- Reduces risk of heart failure hospitalization (Dapagliflozin).
- Slows progression of kidney disease (Dapagliflozin).
Side Effects
- Urinary tract infections (UTIs)
- Genital yeast infections
- Increased urination
- Nasopharyngitis
- Headache
- Joint pain
- Dizziness
- Hypotension
- Ketoacidosis (rare but serious)
- Acute kidney injury
- Fournier's gangrene (very rare)
- Allergic reactions (e.g., rash)
Safety Measures
- Alcohol - Limit alcohol intake as it can increase the risk of dehydration and ketoacidosis, which are potential side effects of SGLT2 inhibitors like dapagliflozin.
- Pregnancy - Not recommended during the second and third trimesters of pregnancy due to potential adverse effects on fetal kidney development from dapagliflozin. Consult your doctor.
- Breastfeeding - It is unknown if sitagliptin or dapagliflozin are excreted in human milk. Due to potential risks to the infant, breastfeeding is not recommended while taking this medication.
- Liver - Sitagliptin may require dose adjustment in moderate to severe hepatic impairment. Dapagliflozin generally does not require dose adjustment for mild to moderate impairment. Use with caution in severe cases.
- Kidney - Sitagliptin dose adjustment is required for moderate to severe renal dysfunction. Dapagliflozin's efficacy is reduced with declining renal function; not recommended for initiation below eGFR 25 mL/min/1.73m².
- Lung - No specific contraindications related to lung conditions. However, ensure adequate hydration, especially in patients with respiratory illnesses that may lead to fluid loss, to prevent acute kidney injury.
Disclaimer
MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.
Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.
Our goal is to complement, not replace, the essential doctor-patient relationship.
| Shipping Cost |
|
| Shop Location | Assam, India |
No comments found for this product. Be the first to comment!